Johnson & Johnson in talks with India for single-dose Covid-19 vaccine Janssen
Apr 09, 2021
New Delhi [India], April 9 : US pharma giant Johnson and Johnson on Friday said it is in discussion with the Government of India to soon begin bridging clinical trials in the country for its single-dose Covid-19 vaccine Janssen.
"At Johnson & Johnson, we remain fully focused on bringing a safe and effective Covid-19 vaccine to people around the world, if authorized for use by local health authorities. We are in discussions with the Government of India with the objective of starting a bridging clinical study of our Janssen Covid-19 vaccine candidate in India, subject to local regulatory approvals," a company statement said.
A bridging study tests the safety and immunogenicity of a vaccine. Janssen vaccine is currently approved for use in the United States, the European Union and other nations including Thailand and South Africa.
India currently has two approved vaccines in use, one developed by Oxford University and AstraZeneca and the other a shot from local player Bharat Biotech.
Faced with a surge in coronavirus cases and heightened demand from states, the country is looking to ramp up its vaccine doses.
The country reported over 1.20 lakh new coronavirus cases in the last 24 hours on Thursday.
With 1,26,789 new cases in the last 24 hours, India's active caseload reached 9,10,319 yesterday.
India recorded 59,258 recoveries were registered in the last 24 hours, taking the cumulative recoveries to 1,18,51,393. The national Recovery Rate is 91.67 per cent.
